Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 6;8(12):e12082.
doi: 10.1016/j.heliyon.2022.e12082. eCollection 2022 Dec.

Orai1 overexpression improves sepsis-induced T-lymphocyte immunosuppression and acute organ dysfunction in mice

Affiliations

Orai1 overexpression improves sepsis-induced T-lymphocyte immunosuppression and acute organ dysfunction in mice

Longwang Chen et al. Heliyon. .

Abstract

Immune paralysis induced by sepsis, especially dysfunction of CD4+ T cells, leads to an increased risk of infection. In sepsis, abnormal differentiation of T lymphocytes is associated with multiorgan dysfunction syndrome. In T lymphocytes, the Orai1/nuclear factor of activated T Cells (NFAT) pathway is a critical mediator of infection, inflammation, and autoimmunity. In this study, we confirmed immunosuppression of splenic CD4+ T cells and abnormal differentiation of T lymphocytes in septic mice. Furthermore, we found that the Orai1/NFAT signaling pathway was inhibited in septic mice; however, the overexpression of Orai1 not only improved immune function of T cells in sepsis but also reduced the mortality and organ damage in septic mice. Moreover, the overexpression of Orai1 could reverse the increases in the numbers of T regulatory and T helper 17 cells in septic mice. These data suggest that the Orai1-mediated NFAT signaling pathway can improve sepsis-induced T-lymphocyte immunosuppression and acute organ dysfunction.

Keywords: Immunosuppression; NFAT; Orai1; Sepsis; Th17; Treg.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Effects of ORAI1 overexpression on organ damage and mortality in septic mice. (A and B) CD4+ T cells were incubated for 30 min with anti-CD3 and anti-CD28 monoclonal antibodies. Expression levels of ORAI1 were measured by western blotting. Results are displayed as the mean ± SD (n = 3). #P < 0.05 vs. the 24-h CLP group, ∗P < 0.05 vs. the sham group. (C) BALB/c mice (n = 60) were randomized into three groups and monitored daily for 7 consecutive days. A Kaplan–Meier curve was plotted to analyze the survival rates, and a log-rank test was used for comparison. #P < 0.05 vs. the 24-h CLP group, ∗P < 0.05 vs. the sham group. (D–F) Renal and hepatic pathological damage was assessed using histology and scores. Representative pathological images are shown for results obtained based on a typical assay. #P < 0.05 vs. the 24-h CLP group, ∗P < 0.05 vs. the sham group.
Figure 2
Figure 2
Effects of ORAI1 overexpression on the proportions of CD3+ and CD8+ T cells in the spleen of septic mice. BALB/c mice were randomized into three groups. The expression of CD3, CD4, and CD8 was detected by flow cytometry. (A) First, CD3+ T cells were circled from total spleen cells, then CD4+ and CD8+ T cells were circled from CD3+ T cells, and finally, Th17 cells and Tregs were circled from CD4+ T cells. (B) Proportion of CD3+ T cells in total cells in each group. Results are displayed as the mean ± SD (n = 6). #P < 0.05 vs. the 24-h CLP group, ∗P < 0.05 vs. the sham group. (C) Proportions of CD4+ and CD8+ cells in CD3+ T cells in each group. Results are displayed as the mean ± SD (n = 6). #P < 0.05 vs. the 24-h CLP group, &P > 0.05 vs. the 24-h CLP group, ∗P < 0.05 vs. the sham group.
Figure 3
Figure 3
Effects of ORAI1 overexpression on the proportions of Th17 cells and Tregs in septic mice. BALB/c mice were randomized into three groups. The proportions of Th17 cells and Tregs in CD4+ T cells from the spleen were examined by flow cytometry. Results are displayed as the mean ± SD (n = 6). #P < 0.05 vs. the 24-h CLP group, ∗P < 0.05 vs. the sham group.
Figure 4
Figure 4
Effects of ORAI1 overexpression on NFAT1 translocation in splenic CD4+ T cells. BALB/c mice were randomized into three 3 groups. NFAT1 translocation was analyzed by laser scanning confocal microscopy. The yellow arrow represents NFAT1 intranuclear transfer. The mean optical density was recorded for statistics. Results are displayed as the mean ± SD. #P < 0.05 vs. the 24-h CLP group, ∗P < 0.05 vs. the sham group.
Figure 5
Figure 5
Effects of ORAI1 overexpression on immune dysfunction of septic splenic CD4+ T-cells. BALB/c mice were randomized into three groups. CD4+ T cells were collected 24 h after the operation. IL-4 and IFN-γ expression in CD4+ T cells was measured by ELISA after 24-h incubation with anti-CD3 and anti-CD28 antibodies. Results are displayed as the mean ± SD (n = 6). ∗P < 0.05. The CCK-8 assay was performed to measure splenic CD4+ T-cell proliferation. #P < 0.05 vs. the 24-h CLP group, ∗P < 0.05 vs. the sham group.
Figure 6
Figure 6
Effects of ORAI1 overexpression on calcium signaling in CD4+ T cells in sepsis. BALB/c mice were randomly divided into three groups. (A and B) [Ca2+]i was measured using Fluo-3. (C) [Ca2+]i was measured using a Fura-2 ratio at 340 and 380 nm. Results are displayed as the mean ± SD (n = 6). #P < 0.05 vs. the 24-h CLP group, ∗P < 0.05 vs. the sham group.

References

    1. Singer M., Deutschman C.S., Seymour C.W., Shankar-Hari M., Annane D., Bauer M., Bellomo R., Bernard G.R., Chiche J.D., Coopersmith C.M., Hotchkiss R.S., Levy M.M., Marshall J.C., Martin G.S., Opal S.M., Rubenfeld G.D., van der Poll T., Vincent J.L., Angus D.C. The third international consensus definitions for sepsis and septic shock (Sepsis-3) JAMA. 2016;315(8):801–810. - PMC - PubMed
    1. Delano M.J., Ward P.A. The immune system's role in sepsis progression, resolution, and long-term outcome. Immunol. Rev. 2016;274(1):330–353. - PMC - PubMed
    1. Fattahi F., Ward P.A. Understanding immunosuppression after sepsis. Immunity. 2017;47(1):3–5. - PubMed
    1. Venet F., Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat. Rev. Nephrol. 2018;14(2):121–137. - PubMed
    1. Hotchkiss R.S., Monneret G., Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat. Rev. Immunol. 2013;13(12):862–874. - PMC - PubMed